19 June 2013
Keywords: genentech, wins, dispute, cancer, drug, patents, federal
Article | 10 May 2001
A US federal court has ruled that two of Genentech's top-sellingproducts, Herceptin (trastuzumab) for breast cancer and Rituxan (rituximab) for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.